Company intelligence / Profile preview

BioMS Medical Corp.

Edmonton, Alberta, Canada6sense.com ↗

Ownership: Private
Employees: ~37
Development stage: Phase 3

Overview

BioMS Medical developed dirucotide (MBP8298), a novel peptide therapy for secondary progressive multiple sclerosis, which advanced to two pivotal Phase III trials in Canada, Europe, and the US. The company entered a major licensing deal with Eli Lilly in 2007 but discontinued clinical development after unsuccessful trial results in mid–2009. Subsequently, the company transitioned into an investment and advisory firm under the name Medwell Capital.

Therapeutic areas: Neurology
Modalities: Peptides (dirucotide/MBP8298 is a therapeutic peptide)
Industry: Investors

Drug pipeline

1 asset

dirucotide

Phase 3

Indications: Secondary progressive multiple sclerosis, Relapsing remitting multiple sclerosis

Partnerships

Eli Lilly & Company (exclusive worldwide license for dirucotide/MBP8298)

Beyond the preview

Go deeper on BioMS Medical Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMS Medical Corp..

Explore the full profile